| Human immunodeficiency virus I infection
Apretude vs Rukobia
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Apretude vs Rukobia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRukobia has a higher rate of injection site reactions vs Apretude based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rukobia but not Apretude, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Apretude
Rukobia
At A Glance
IM injection
Every 2 months
HIV integrase strand transfer inhibitor
Oral
Twice daily
HIV-1 attachment inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 600-mg (3-mL) gluteal IM initiation injections 1 month apart for 2 consecutive months, then 600-mg (3-mL) every 2 months; optional oral lead-in with cabotegravir 30 mg once daily for at least 28 days prior to first injection.
Human immunodeficiency virus I infection 600 mg orally twice daily with or without food; swallow tablets whole, do not chew, crush, or split.
Contraindications
- Unknown or positive HIV-1 status
- Previous hypersensitivity reaction to cabotegravir
- Coadministration with anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin) due to significant UGT1A1 induction decreasing cabotegravir plasma concentrations
- Coadministration with antimycobacterials rifampin or rifapentine due to significant UGT1A1 induction decreasing cabotegravir plasma concentrations
- Previous hypersensitivity to fostemsavir or any component of RUKOBIA
- Coadministration with strong CYP3A inducers, including enzalutamide, carbamazepine, phenytoin, rifampin, mitotane, and St John's wort (Hypericum perforatum)
Adverse Reactions
Most common (>=1%) Injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back pain, upper respiratory tract infection
Serious Hypersensitivity reactions, hepatotoxicity, depressive disorders including depression, suicidal ideation, and suicide attempt
Postmarketing Hypersensitivity reactions (angioedema, urticaria), Stevens-Johnson syndrome/toxic epidermal necrolysis
Most common (>=2%) Nausea, diarrhea, headache, abdominal pain, dyspepsia, fatigue, rash, sleep disturbance, immune reconstitution inflammatory syndrome, somnolence, vomiting
Serious Immune reconstitution inflammatory syndrome, QTc prolongation, hepatic transaminase elevations in patients with hepatitis B or C virus co-infection
Pharmacology
Cabotegravir is an HIV integrase strand transfer inhibitor (INSTI) that inhibits HIV replication by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, which is essential for the HIV replication cycle.
HIV-1 attachment inhibitor; fostemsavir is a prodrug hydrolyzed to temsavir, which binds directly to the gp120 subunit of the HIV-1 envelope glycoprotein and selectively inhibits the interaction between the virus and cellular CD4 receptors, preventing viral attachment and subsequent entry into host cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Apretude
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Rukobia
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Apretude
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rukobia
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Apretude
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Rukobia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Apretude Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ApretudeView full Apretude profile
RukobiaView full Rukobia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.